Whitehawk Therapeutics, Inc. (WHWK)
NASDAQ: WHWK · Real-Time Price · USD
2.490
-0.070 (-2.73%)
At close: Dec 5, 2025, 4:00 PM EST
2.480
-0.010 (-0.40%)
After-hours: Dec 5, 2025, 7:57 PM EST
Whitehawk Therapeutics Revenue
Whitehawk Therapeutics had revenue of $14.38M in the twelve months ending September 30, 2025, down -42.62% year-over-year. In the year 2024, Whitehawk Therapeutics had annual revenue of $25.98M with 6.69% growth.
Revenue (ttm)
$14.38M
Revenue Growth
-42.62%
P/S Ratio
8.89
Revenue / Employee
$359,600
Employees
40
Market Cap
117.35M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 25.98M | 1.63M | 6.69% |
| Dec 31, 2023 | 24.35M | 9.14M | 60.06% |
| Dec 31, 2022 | 15.22M | 14.10M | 1,258.57% |
| Dec 31, 2021 | 1.12M | -13.46M | -92.32% |
| Dec 31, 2020 | 14.58M | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | 20.16M | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | - | - | - |
| Dec 31, 2010 | - | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
WHWK News
- 5 days ago - Whitehawk Therapeutics Appoints Margaret Dugan, MD, as Chief Medical Officer - PRNewsWire
- 10 days ago - Whitehawk Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference - PRNewsWire
- 25 days ago - Whitehawk Therapeutics to Present at Jefferies Global Healthcare Conference in London - PRNewsWire
- 4 weeks ago - Whitehawk Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights - PRNewsWire
- 6 weeks ago - Whitehawk Therapeutics Presents Real-World Analysis Confirming PTK7 as a Broadly Expressed, Clinically Relevant Target Across Solid Tumors at AACR-NCI-EORTC - PRNewsWire
- 7 weeks ago - Tempus Announces Collaboration with Whitehawk Therapeutics to Advance Biomarker-Driven Oncology Research - Business Wire
- 3 months ago - Whitehawk Therapeutics, Inc. (WHWK) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 3 months ago - Whitehawk Therapeutics to Participate in Upcoming Investor Conferences - PRNewsWire